Skip to main navigation

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Home

Social Links

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

SEC Filing Details

  • Home
  • Investor Relations
  • SEC Filings
  • 3

IR Menu

IR Home
Press Releases
Events & Presentations
Corporate Governance
Stock Information
SEC Filings
Analyst Coverage
Information Request
FAQs

« Back

Document Details

Form
3
Filing Date
06/06/22
Document Date
06/06/22
Form Description
Initial filing by director officer or owner of more than ten percent.
Filing Group
3,4,5
Company
Sarepta Therapeutics, Inc.
Issuer
SAREPTA THERAPEUTICS, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Toolkit

Print Page | Email Alerts | RSS Feeds | Contacts

Follow Us On Social

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

©2023 Sarepta Therapeutics, Inc. All rights reserved.

Footer Utility Nav

  • Privacy Policy
  • Terms of Use
  • EU-U.S. and Swiss-U.S. Privacy Shield Policy